{
  "id": "cluster_6_doc1",
  "content": "Aurora Valley Hospital reported a 37% increase in gene therapy claims during Q3 2024, primarily for RDEB patients aged 18-30. Policy GT-225R expansion allowed coverage of experimental treatments. Dr. Elara Voss noted improved outcomes in 68% of cases, with particular success in compound heterozygotes. The regional pharmacy network struggled with distribution logistics for these specialized biologics.",
  "metadata": {
    "format": "insurance_memo"
  }
}